MARKET

CDTX

CDTX

Cidara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.390
-0.080
-3.24%
Closed 16:00 04/02 EDT
OPEN
2.470
PREV CLOSE
2.470
HIGH
2.470
LOW
2.280
VOLUME
132.39K
TURNOVER
--
52 WEEK HIGH
4.440
52 WEEK LOW
1.223
MARKET CAP
96.83M
P/E (TTM)
-1.8624
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CDTX stock price target is 6.61 with a high estimate of 10.00 and a low estimate of 4.000.

EPS

CDTX News

More
  • What Makes Cidara Therapeutics (CDTX) a New Buy Stock
  • Zacks · 2d ago
  • Needham Maintains Buy on Cidara Therapeutics, Lowers Price Target to $6
  • Benzinga · 03/05 12:44
  • Cidara Therapeutics EPS beats by $0.01, misses on revenue
  • seekingalpha · 03/04 16:00
  • Cidara Therapeutics (CDTX) Reports Q4 Loss, Misses Revenue Estimates
  • Zacks · 03/04 12:30

Industry

Biotechnology & Medical Research
+3.33%
Pharmaceuticals & Medical Research
+2.80%

Hot Stocks

Symbol
Price
%Change

About CDTX

Cidara Therapeutics Inc., is a clinical-stage biotechnology company focused on developing new anti-infectives. The Company’s lead product candidate is rezafungin acetate, which is a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates. The Company is also leveraging its novel Cloudbreak platform to develop antibody-drug conjugates for the treatment of serious viral and Gram-negative bacterial infections. Cloudbreak is the immunotherapy discovery platform designed specifically to create compounds that directly kill pathogens and also direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens.
More

Webull offers kinds of Cidara Therapeutics Inc stock information, including NASDAQ:CDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDTX stock news, and many more online research tools to help you make informed decisions.